Could CRISPR cure HIV? US biotech Excision raises $60m to find outUS biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which Share XCould CRISPR cure HIV? US biotech Excision raises $60m to find outhttps://pharmaphorum.com/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out/
ViiV’s Rukobia cleared in EU as rescue HIV therapyThe European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment Share XViiV’s Rukobia cleared in EU as rescue HIV therapyhttps://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/
ViiV/J&J’s long-acting HIV regimen finally approved in USThe FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the Share XViiV/J&J’s long-acting HIV regimen finally approved in UShttps://pharmaphorum.com/news/fda-finally-approves-viiv-jjs-long-acting-hiv-regimen/
ViiV launches digital triage service for HIV patients with London hospitalViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients Share XViiV launches digital triage service for HIV patients with London hospitalhttps://pharmaphorum.com/news/viiv-launches-digital-triage-service-for-hiv-patients-with-london-hospital/
Tivicay approved in Europe in new dispersible tablet for children with HIVViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living Share XTivicay approved in Europe in new dispersible tablet for children with HIVhttps://pharmaphorum.com/news/tivicay-approved-in-europe-in-new-dispersible-tablet-for-children-with-hiv/
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirGilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug Share XData sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirhttps://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/
ViiV could challenge Gilead with long-acting HIV PrEP shotGlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after Share XViiV could challenge Gilead with long-acting HIV PrEP shothttps://pharmaphorum.com/news/viiv-could-challenge-gilead-with-long-acting-hiv-prep-shot/
Finding resilience after an HIV diagnosisAuthor and journalist John-Manuel Andriote has spent much of his career writing about the impact of HIV/AIDS – Share XFinding resilience after an HIV diagnosishttps://pharmaphorum.com/views-analysis-patients/finding-resilience-hiv-diagnosis/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
